The threshold dose for AMR-001 was prospectively established in the Phase I trial.
- Increasing doses of AMR-001 reduced the size of the infarct region
- Increasing doses of AMR-001 reduced RTSS (hypoperfusion)
Patients dosed >= the threshold dose of 10 million cells showed significant improvement in perfusion
|
RTSS (Hypoperfusion)
|
||||
|
Cohort
|
Base Line
|
6 months
|
Delta
|
% Change
|
|
Control
|
259.0
|
273.5
|
+14.5
|
+5.6
|
|
5 M
|
714.2
|
722.0
|
+7.8
|
+1.1
|
|
10 M
|
998.6
|
635.8
|
-362.8
|
-36.4
|
|
15 M
|
584.0
|
462.0
|
-122.0
|
-20.9
|
Quick Links
Copyright © 2010-2012 NeoStem, Inc.
Privacy Policy | Forward Looking Statements | Terms of Use | Social Media Policy | Site Map
Members of the NeoStem Family
